Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (301) clinical trials

Deferasirox in Treating Patients With Very Low Low or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

PRIMARY OBJECTIVES: I. To assess the activity of iron chelation therapy (ICT) with deferasirox, in patients with anemia as a result of myelodysplastic syndrome (MDS). SECONDARY OBJECTIVES: I. Reduction in red blood cell (RBC) transfusion requirements. II. Hematologic improvement. III. Change in serum ferritin levels from baseline to the end ...

Phase

Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)

Study Drug Administration: Each study cycle is 4 weeks (28 days). Participant will receive azacitidine either by vein over about 10-40 minutes or as an injection under the skin for 7 days starting on Days 1 of each cycle. If participant is receiving azacitidine at a clinic that closes over ...

Phase

Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome

The study will enroll 20 eligible subjects who will receive NK cell infusion to test whether infusion of expanded activated NK cells can produce measurable clinical responses in patients with AML/MDS or T-ALL.The study aims to infuse a target dose of 10 x 107 CD56+ cells/kg, however, as the actual ...

Phase

Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)

Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for researchers, clinicians, patients, and health care underwriters such as Medicare, is the role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment ...

Phase

Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease

The induction of transplantation tolerance involves the specific elimination of the immune response to the transplant but not to other antigens. In the realm of kidney transplantation, tolerance means that the recipient is unable to detect the donor transplant kidney as foreign, and therefore the recipient is unable to reject ...

Phase N/A

Shorter Course Tacro After NMA Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

The main goal is to learn whether a drug called tacrolimus, which is an immune-lowering drug (an immunosuppressant) given after transplant to help prevent certain complications, can be given safely for a shorter period of time than it has been in the past. The experiences with immunosuppression duration with other ...

Phase

Chemotherapy Total Body Irradiation and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

PRIMARY OBJECTIVES: I. To determine the cumulative incidence of extensive chronic graft versus host disease (GVHD) at 1 year after transplantation utilizing the novel conditioning/GVHD prophylactic regimen for patients undergoing allogeneic hematopoietic cell transplantation, in patients who do not progress before day 100. SECONDARY OBJECTIVES: I. To evaluate clinical response, ...

Phase

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS

The purpose of this study is to compare safety and efficacy of reduced-intensity conditioning and myeloablative conditioning regimens prior to HSCT in high-risk AML/MDS pediatric and young adult patients. This study investigates the use of two novel conditioning therapies for hematopoietic stem cell transplant (HSCT). The primary focus of both ...

Phase

Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG

This study is examining a chemotherapy regimen and immune suppressive medications in the setting of an allogeneic stem cell transplant. A pilot clinical trial to characterize the incidence, prevalence and function of myeloid-derived suppressor cells (MDSCs) and immune checkpoint regulators (V-domain Ig Suppressor of T-cell Activation [VISTA], cytotoxic T-lymphocyte- associated ...

Phase

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

To make donor derived multiTAA-specific T cells, the investigators will collect blood from the patient's stem cell donor, and mix the donor's T cells with small pieces of tumor proteins WT1, PRAME, NY-ESO-1, and Survivin. These protein fragments stimulate the donor T cells to grow and react against these proteins ...

Phase